<DOC>
	<DOCNO>NCT00032019</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining rituximab combination chemotherapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine rituximab combination chemotherapy treat patient previously untreated non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Monoclonal Antibody Therapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , progression-free survival , overall survival patient previously untreated aggressive CD20+ B-cell diffuse large cell immunoblastic large cell lymphoma treat rituximab , doxorubicin , etoposide , vincristine , prednisone , cyclophosphamide . - Determine toxic effect regimen patient . - Correlate tumor proliferation rate ( MIB-1 ) , bcl-2 expression , p53 overexpression complete response rate , progression-free survival , overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive rituximab IV day 1 ; doxorubicin IV continuously , etoposide IV continuously , vincristine IV continuously day 1-4 ; oral prednisone twice daily day 1-5 ; cyclophosphamide IV day 5 . Patients also receive filgrastim ( G-CSF ) subcutaneously begin day 6 continue blood count recover . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . After 4 course , patient complete partial response receive 2 additional course . Patients follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 25-50 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II , III , IV diffuse large cell lymphoma WHO variants CD20+ large Bcell lymphoma , include immunoblastic feature CD20+ thymic Bcell lymphoma No evidence indolent lymphoma No mantle cell lymphomas equivocal Bcell lymphoma express marker mantle cell lymphoma ( e.g. , cyclin D ) subtypes No know lymphomatous involvement CNS , include parenchyma leptomeninges PATIENT CHARACTERISTICS : Age : Not specify Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm3* Platelet count least 100,000/mm3* NOTE : * Unless due lymphoma Hepatic : Bilirubin great 2.0 mg/dL* NOTE : * Unless due lymphoma Gilbert 's disease Renal : Creatinine great 1.5 mg/dL* NOTE : * Unless due lymphoma Cardiovascular : LVEF great 45 % No ischemic heart disease No myocardial infarction congestive heart failure within past year Other : HIV negative Not pregnant nurse Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy No concurrent chemotherapy Endocrine therapy : Prior shortcourse glucocorticoid allow No concurrent hormones except nondiseaserelated condition ( e.g. , insulin diabetes ) No concurrent steroid except adrenal failure No concurrent dexamethasone steroidal antiemetic Radiotherapy : Prior limitedfield radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
</DOC>